ÂÜÀòÂÒÂ×

He brings more than 19 years of experience in research and development, venture capital, and business development to Orna and most recently served as Chief Operating Officer at Virtuoso Therapeutics. Prior to Virtuoso, Will was the Head of M&A at Biogen from 2019 to 2021. During his tenure at Biogen, he also served as the Interim Head of Corporate Development for most of 2020, overseeing M&A, BD&L, Strategy, and Alliance Management. Under his leadership, Biogen completed more than 15 business development transactions in 2020, including partnerships with Denali and Sage, two of the largest transactions in Neuroscience that year. Prior to Biogen, Will was an M&A Lead at BMS, where he led the acquisition of IFM and Cardioxyl, as well as the option agreement to acquire Promedior. Before joining the industry as a business development executive, Will was a venture investor at venBio and Johnson & Johnson Development Corporation.